Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

BACKGROUND: Namodenoson, an A3 adenosine receptor (A3AR) agonist, improved liver function/pathology in non‐alcoholic steatohepatitis (NASH) preclinical models. AIM: To evaluate the efficacy and safety of namodenoson for the treatment of non‐alcoholic fatty liver disease (NAFLD) with or without NASH...

Descripción completa

Detalles Bibliográficos
Autores principales: Safadi, Rifaat, Braun, Marius, Francis, Adi, Milgrom, Yael, Massarwa, Muhammad, Hakimian, David, Hazou, Wadi, Issachar, Assaf, Harpaz, Zivit, Farbstein, Motti, Itzhak, Inbal, Lev‐Cohain, Naama, Bareket‐Samish, Avital, Silverman, Michael H., Fishman, Pnina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298378/
https://www.ncbi.nlm.nih.gov/pubmed/34671996
http://dx.doi.org/10.1111/apt.16664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298378/
https://www.ncbi.nlm.nih.gov/pubmed/34671996
http://dx.doi.org/10.1111/apt.16664

Ejemplares similares